Tag Archives: bad-request

Gilead Gets Wall Street Love After Q2 Earnings Beat

Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and the increased guidance, from a company known for conservative forecasting. Piper Jaffray analyst Joshua Schimmer raised his price target on Gilead stock to 134 from 131 based on the news. “While the

Tableau Tumbles As Earnings Beat Not (Really) A Beat

Tableau Software (DATA) stock crashed Wednesday, losing more than a fifth of its value, after its earnings and outlook beat official Wall Street expectations but missed the higher expectations many investors had for what had been a high-flying stock. “Tableau has handily exceeded consensus revenue estimates every quarter of its tenure as a public company by an average of $12.5 million, or 16.4%,” D.A. Davidson analyst Jack Andrews wrote in a

NuVasive Hits 7-Year High After Q2 Earnings Beat

Spinal-product specialist NuVasive (NUVA) got an upgrade and two price-target increases Wednesday after its Q2 earnings beat estimates late Tuesday. The stock hit a seven-year high in early trading. NuVasive’s profit rose 11% over the year-earlier quarter to 31 cents a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Sales rose 6% to $202.9 million, about $2 million above estimates. NuVasive added 7 cents to its